Bifidobacterium breve A1 is a proprietary strain of probiotic bacteria isolated from the intestinal tract of an infant. A main component of the human gut microbiome, Bifidobacteria species form part ...

Most scientists agree that age-related immune dysfunction—in one form or another—factors strongly into Alzheimer’s and other neurodegenerative diseases. The mechanisms involved are far less settled, ...

More flies can be caught with sugar than with vinegar, the saying goes. But to nab people with neurodegeneration, the vinegar might be best—it’s acetic acid, at least. At ADPD 2026 in Copenhagen, ...

Once more than 4 percent of tau molecules in a person’s blood are phosphorylated at residue 217, the clock starts ticking—toward the first symptoms of Alzheimer’s disease, that is. How long it might ...

People who consume copious fruits and vegetables tend to enjoy healthier, longer lives, and are less prone to dementia. How could noshing on plants ward off age-related diseases such as Alzheimer’s?

Exercise helps stave off Alzheimer’s disease, but exactly how it does so is murky. In the February 18 Cell, scientists led by Saul Villeda at the University of California, San Francisco, offered one ...

Post-marketing data chart immunotherapy performance in early-onset Alzheimer’s. The antibodies lowered amyloid and slowed functional decline. However, tangles continued to form. “These results offer ...

If a person with no cognitive complaints tests positive for brain amyloid based on plasma p-tau217, what should their doctor tell them about their likelihood of getting Alzheimer’s disease? That’s the ...

As the brain’s fluid drainage systems become sluggish with age, troublemakers such as amyloid and tau aggregates start to build up. To flush out disease-causing detritus, neurosurgeons in China have ...

More antibodies take aim at seeded propagation. New data ties tangle location to deficits in specific cognitive domains. Three first-in-human studies for antibodies targeting different parts of tau ...

On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...